What is HC Wainwright’s Estimate for ImageneBio Q3 Earnings?

ImageneBio, Inc. (NASDAQ:IMA) – Equities researchers at HC Wainwright issued their Q3 2026 earnings estimates for ImageneBio in a research note issued to investors on Friday, August 21st. HC Wainwright analyst S. Ramakanth expects that the company will post earnings of ($0.98) per share for the quarter. HC Wainwright has a “Buy” rating and a $28.00 price target on the stock. The consensus estimate for ImageneBio’s current full-year earnings is ($3.07) per share. HC Wainwright also issued estimates for ImageneBio’s Q4 2026 earnings at ($1.02) EPS, FY2026 earnings at ($3.57) EPS, Q1 2027 earnings at ($1.14) EPS, Q2 2027 earnings at ($1.28) EPS, Q3 2027 earnings at ($1.44) EPS, Q4 2027 earnings at ($1.62) EPS, FY2027 earnings at ($5.48) EPS, FY2028 earnings at ($5.07) EPS, FY2029 earnings at ($4.73) EPS and FY2030 earnings at ($4.61) EPS.

ImageneBio (NASDAQ:IMA) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.27.

Other research analysts have also issued reports about the company. Wedbush reissued an “underperform” rating on shares of ImageneBio in a report on Monday, May 11th. Wall Street Zen lowered shares of ImageneBio from a “sell” rating to a “strong sell” rating in a research report on Sunday, May 17th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of ImageneBio in a research note on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $29.00.

ImageneBio Stock Up 2.0%

Shares of NASDAQ IMA opened at $5.62 on Tuesday. ImageneBio has a twelve month low of $3.94 and a twelve month high of $14.34. The company has a market cap of $63.79 million, a PE ratio of -1.23 and a beta of 0.76. The business’s 50 day moving average price is $5.79 and its two-hundred day moving average price is $5.85.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Blue Owl Capital Holdings LP bought a new position in ImageneBio during the second quarter worth about $5,414,000. Deep Track Capital LP bought a new stake in ImageneBio in the 3rd quarter valued at about $7,160,000. Cable Car Capital LP bought a new stake in ImageneBio in the 2nd quarter valued at about $4,611,000. Trails Edge Capital Partners LP bought a new stake in ImageneBio in the 2nd quarter valued at about $1,663,824,000. Finally, Vanguard Group Inc. acquired a new position in shares of ImageneBio during the 3rd quarter worth approximately $1,902,000. Institutional investors own 75.00% of the company’s stock.

Key Stories Impacting ImageneBio

Here are the key news stories impacting ImageneBio this week:

• Positive Sentiment: HC Wainwright initiated research coverage on ImageneBio with a Buy rating and a $28.00 price target, substantially above the stock’s recent trading level. The bullish rating and large implied upside provide the main positive catalyst for IMA shares. ImageneBio Research Coverage Started at HC Wainwright
• Positive Sentiment: The analyst’s current-year loss estimate of $3.07 per share is less pessimistic than HC Wainwright’s separate FY2026 estimate of a $3.57-per-share loss, suggesting expectations may improve over the near term. The company also recently exceeded quarterly EPS expectations, providing additional support for investor sentiment.
• Neutral Sentiment: HC Wainwright projects losses of $0.98 per share in Q3 2026 and $1.02 in Q4 2026, followed by quarterly losses of $1.14, $1.28, $1.44 and $1.62 through Q4 2027. The firm forecasts full-year losses of $5.48 in FY2027, $5.07 in FY2028, $4.73 in FY2029 and $4.61 in FY2030, underscoring that the investment case depends on future clinical or commercial progress rather than near-term profitability.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.